Thomas J Herzog

9PUBLICATIONS
56CO-AUTHORS
Predictive and prognostic markersMolecular targetsEpigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Horticultural crop improvement (incl. selection and breeding)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 10, 2026
Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.

|Dec 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Brian M Slomovitz, S John Weroha, Wei Deng

|Dec 02, 2025
Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities.

Vivek Podder, Robert L Coleman, Andrea R Hagemann

|Oct 31, 2025
Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.

Bradley J Monk, Robert L Coleman, David M O'Malley

|Nov 20, 2024
Analysis of Concordance Between Next-Generation Sequencing Assessment of Microsatellite Instability and Immunohistochemistry-Mismatch Repair From Solid Tumors.

Rouba Ali-Fehmi, Harris Benjamin Krause, Robert T Morris

|Nov 06, 2023
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.

Thomas J Herzog, Shaun A Wahab, Mansoor R Mirza

Pageof 2

Frequent Collaborators

4 joint publications

Robert L Coleman

3 joint publications

Brian M Slomovitz

3 joint publications

Bradley J Monk

2 joint publications

Antonio González-Martin